The abovementioned results may provide a solid foundation for uncovering the oncogenic role of aberrant glycosylation of SEMA7A in HNSCC, thus further improving therapeutic efficacy. This evidence concerns the gene SEMA7A and head and neck squamous cell carcinoma.